Background: Tacrolimus (TAC) is the cornerstone of immunosuppression after liver transplantation (LT). TAC has a narrow therapeutic index and high inter- and intra-individual pharmacokinetic (PK) variability, requiring dose individualization. This variability is more noticeable in the early post-LT period. Objectives: This study aimed to compare the PK of different TAC formulations in the early post-LT period and describe the main PK characteristics and plasma levels obtained with each TAC formulation used. Methods: The search was conducted in MEDLINE (PubMed) and EMBASE in accordance with PRISMA-ScR guidelines. The main inclusion criteria were clinical trials and observational studies focusing on the PK parameters of TAC in LT recipients during the first month post-transplant. Results: A total of 2169 articles were identified, of which 23 met the inclusion criteria. Various PK parameters were analyzed after LT for the different TAC formulations: intravenous (iv) and oral forms, such as immediate-release (IRT), prolonged-release (PRT), and extended-release (LCPT) formulations. PK variability was higher in the initial days after LT, with different TAC exposure between formulations. IV TAC allows the rapid attainment of therapeutic levels, but it has fallen into disuse. Regarding oral formulations, IRT reaches target levels faster than PRT and LCPT. PRT and LCPT exposure seem more stable during the first month post-LT than when using IRT. Conclusions: TAC formulations exhibit relevant differences in their PK profile in the early post-LT period. PK differences might influence the dose regimen and the time to achieve PK targets. Given these variations, therapeutic drug monitoring (TDM) is essential for optimizing treatment.

Background: Highly specialized therapies such as chimeric antigen receptor T-cell (CAR T-cell) therapy, bispecific antibodies (BsAbs), and hematopoietic stem cell transplantation (HSCT) have substantially improved outcomes for patients with high-risk or relapsed hematologic malignancies. These therapies are associated with potentially severe toxicities requiring close clinical monitoring, particularly during transitions across care settings. Digital health interventions have been proposed to facilitate symptom reporting, adverse events (AEs) detection, and continuity of care. Objective: To map and describe evidence on digital health interventions used for clinical monitoring and early detection and management of AEs in adults with hematologic malignancies receiving highly specialized therapies, including CAR T-cell therapy, BsAbs, and HSCT. Methods: The review will be conducted following the Joanna Briggs Institute ( JBI) methodology for scoping reviews and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Eligibility criteria will be defined according to the Population–Concept–Context (PCC) framework recommended by the JBI methodology. Searches will be undertaken in MEDLINE, EMBASE, Cochrane Library, Web of Science, Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and selected grey literature sources. Two independent reviewers will screen studies and extract data using a data charting form that will be piloted before full data extraction. Results will be synthesized descriptively and presented in tabular and narrative formats. The searches will cover all records available from database inception to 18 February 2026, with no restrictions on language or publication date. Conclusions: This scoping review will map the available evidence on digital health interventions for patients with hematologic malignancies receiving CAR T-cell therapy, BsAbs, or HSCT, identify knowledge gaps, and inform future research in this emerging field.